CClinicalTrials.gg
CompletedNCT04653792Updated Dec 4, 2020

Role Of Pregabalin To Decrease Postoperative Pain In Microdiscectomy

A Phase 4 interventional study of Pregabalin 75mg and Placebo in Pain, Nerve and Prolapsed Intervertebral Disc, sponsored by Ziauddin University. Completed at 1 site in Pakistan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-04.

Sponsored by Ziauddin University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 5 months ago, and no results have been posted to the registry.
  • Registered 2 years 5 months after the study started (first participant enrolled Jun 2018, registered Nov 2020).
Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to compare the effect of pregabalin in reducing the neuropathic pain in postoperative patients who have undergone single level Microdiscectomy for prolapsed intervetebral lumbar disc.

Read the detailed description

All patients were informed in detailed regarding the risk and complications and given written and informed consent, coming to our clinics were assessed by one of the senior team members of the spine, patient fulfilling the eligibility criteria were selected and included in the study. One week before the surgery the patients who met the eligibility criteria were randomized in a double-blind manner (participant and investigator) in a ratio of 1:1 into Group-A (Pregabalin 7mg, twice daily) or Group-B (Placebo, twice daily). The pain scores were recorded by VAS and Roland Morris score system on preoperative day compared to the scores on the 1st week postoperative follow-up.

02

Conditions studied

  • Pain, Nerve
  • Prolapsed Intervertebral Disc

Keywords

  • Microdiscectomy
  • Pregabalin
03

In context

Intervertebral Disc Displacement

478 studies on the registry are indexed under Intervertebral Disc Displacement; 104 are open to participants now.

This study's enrollment of 84 is above the median of 63 across 344 interventional studies indexed under Intervertebral Disc Displacement.

Browse Intervertebral Disc Displacement studies →

Lead sponsor

Ziauddin University is the lead sponsor of 48 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients with severe CLBP and/or leg pain
  • Patients with static or dynamic leg pain
  • Patients with leg pain resulting from localized lumbar or lumbosacral segmental instability
  • Spinal stenosis at levels L2-S1 or caused by isthmic spondylolisthesis (grade I and II)

Exclusion criteria

Exclusion Criteria:

  • Patients with previous lumbar surgery
  • Patients allergic to gabapentinoids
  • Patients with renal impairments
  • Patients who are already on opioids, benzodiazepines, barbiturates, ethanol (alcohol)
  • Patient presented with diabetes and other drugs that depress the central nervous system
  • Patients who are already on ACE inhibitors as they may enhance the adverse/toxic effect of Pregabalin.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Participants received Pregabalin 75mg capsule twice daily from preoperative day to 1 week postoperative

    Drug: Pregabalin 75mg

  • Placebo comparator
    Pregabalin Placebo

    Participants received Pregabalin placebo capsule matching Pregabalin twice daily from preoperative day to 1 week postoperative

    Device: Placebo

Interventions

  • DrugPregabalin 75mg

    75 mg capsule

    Also known as: Lyrica (Pregabalin) 75mg

  • DevicePlacebo

    75 mg

    Also known as: Pregabalin placebo

06

What researchers measure

Primary outcomes

  1. change from preoperative pain score using a 10 point visual analog scale (VAS pain scale) at 1 week post surgery for PID

    VAS pain scale is a validated, self-reported instrument assessing average pain intensity over the past 24 hours period. Possible scores being 0 (no pain) and 10 (worst possible pain). Change = (1 week post surgery - preoperative pain)

    Time frame: Preoperative and one week postoperative

07

Study locations

1 site
  • Dr. Ziauddin University Hospital Clifton Campus
    Karachi, Sindh 75600, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04653792
Lead sponsor
Ziauddin University
Responsible party
Shahzaib Riaz Baloch (Senior Resident, Orthopedics Department, Ziauddin University) — Principal investigator
First posted
Dec 4, 2020
Start date
Jun 4, 2018
Primary completion
Apr 17, 2020
Completion
Apr 17, 2020
Last update
Dec 4, 2020

Study contacts

Shahzaib Riaz
principal investigator · Ziauddin University hospital Karachi
Sohail Rafi, FCPS
study director · Ziauddin University Hospital Karachi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion